Eris Lifesciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Amit Bakshi

Chief executive officer

₹48.8m

Total compensation

CEO salary percentage	35.9%
CEO tenure	17.3yrs
CEO ownership	42.9%
Management average tenure	7.7yrs
Board average tenure	3.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Amit Bakshi's remuneration changed compared to Eris Lifesciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹4b
Sep 30 2023	n/a	n/a	₹4b
Jun 30 2023	n/a	n/a	₹4b
Mar 31 2023	₹49m	₹17m	₹4b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹4b
Jun 30 2022	n/a	n/a	₹4b
Mar 31 2022	₹46m	₹26m	₹4b
Dec 31 2021	n/a	n/a	₹4b
Sep 30 2021	n/a	n/a	₹4b
Jun 30 2021	n/a	n/a	₹4b
Mar 31 2021	₹27m	₹27m	₹4b
Dec 31 2020	n/a	n/a	₹3b
Sep 30 2020	n/a	n/a	₹3b
Jun 30 2020	n/a	n/a	₹3b
Mar 31 2020	₹49m	₹18m	₹3b
Dec 31 2019	n/a	n/a	₹3b
Sep 30 2019	n/a	n/a	₹3b
Jun 30 2019	n/a	n/a	₹3b
Mar 31 2019	₹49m	₹18m	₹3b
Dec 31 2018	n/a	n/a	₹3b
Sep 30 2018	n/a	n/a	₹3b
Jun 30 2018	n/a	n/a	₹3b
Mar 31 2018	₹49m	₹11m	₹3b

Compensation vs Market: Amit's total compensation ($USD584.34K) is above average for companies of similar size in the Indian market ($USD433.43K).

Compensation vs Earnings: Amit's compensation has been consistent with company performance over the past year.

CEO

Amit Bakshi (47 yo)

17.3yrs

Tenure

₹48,776,648

Compensation

Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Amit Bakshi	Chairman & MD	no data	₹48.78m	42.88% ₹ 52.3b
Vijay Joshi	President	no data	₹12.31m	no data
Sachin Shah	Chief Financial Officer	7.7yrs	₹14.35m	no data
Krishnakumar Vaidyanathan	Executive Director & COO	3yrs	₹44.85m	no data
Milind Talegaonkar	Compliance Officer & Company Secretary	7.7yrs	no data	no data
Gagan Atreja	President of Sales & Marketing	no data	₹11.24m	no data
Inderjeet Negi	Executive Director	no data	₹12.40m	4.37% ₹ 5.3b
Kaushal Shah	Whole Time Director	no data	₹6.99m	3.28% ₹ 4.0b
Deepak Kapoor	Senior Vice President	no data	₹12.64m	no data
Alok Mahajan	Vice President	no data	₹13.30m	no data
Santanu Rudra	Vice President	no data	₹10.67m	no data
Santosh Danavale	Vice President	no data	₹13.12m	no data

7.7yrs

Average Tenure

49.5yo

Average Age

Experienced Management: 540596's management team is seasoned and experienced (7.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Amit Bakshi	Chairman & MD	17.3yrs	₹48.78m	42.88% ₹ 52.3b
Krishnakumar Vaidyanathan	Executive Director & COO	3.4yrs	₹44.85m	no data
Inderjeet Negi	Executive Director	17.3yrs	₹12.40m	4.37% ₹ 5.3b
Kaushal Shah	Whole Time Director	3.8yrs	₹6.99m	3.28% ₹ 4.0b
Prashant Gupta	Independent Director	6.1yrs	₹3.98m	no data
Sujesh Vasudevan	Independent Director	1.8yrs	₹2.82m	no data
Kalpana Unadkat	Independent Director	3.3yrs	₹4.53m	no data
Rajeev Dalal	Independent Director	3.4yrs	₹4.20m	no data

3.6yrs

Average Tenure

49yo

Average Age

Experienced Board: 540596's board of directors are considered experienced (3.6 years average tenure).

Eris Lifesciences Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Insider recently sold ₹1.6m worth of stock

Eris Lifesciences Limited, Annual General Meeting, Sep 25, 2023

Chairman & MD recently bought ₹7.2m worth of stock

Chairman & MD recently bought ₹128m worth of stock

Chairman & MD recently bought ₹109m worth of stock

Recent updates

Now 21% undervalued after recent price drop

Eris Lifesciences Limited (NSEI:ERIS) completed the acquisition of 51% stake in Swiss Parenterals Limited.

Eris Lifesciences Limited (NSEI:ERIS) agreed to acquire 51% stake in Swiss Parenterals Limited INR6.4 billion.

Third quarter 2024 earnings released: EPS: ₹7.55 (vs ₹7.49 in 3Q 2023)

Eris Lifesciences Limited to Report Q3, 2024 Results on Feb 13, 2024

Insufficient new directors

Now 22% overvalued after recent price rise

Eris Lifesciences Limited (NSEI:ERIS) entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.

Second quarter 2024 earnings: EPS exceeds analyst expectations

Eris Lifesciences Limited to Report Q2, 2024 Results on Nov 08, 2023

Insider recently sold ₹1.6m worth of stock

New major risk - Dividend sustainability

Eris Lifesciences Limited, Annual General Meeting, Sep 25, 2023

First quarter 2024 earnings released: EPS: ₹6.97 (vs ₹6.96 in 1Q 2023)

Eris Lifesciences Limited to Report Q1, 2024 Results on Aug 07, 2023

Full year 2023 earnings: EPS misses analyst expectations

Eris Lifesciences Limited to Report Q4, 2023 Results on May 17, 2023

Chairman & MD recently bought ₹7.2m worth of stock

Chairman & MD recently bought ₹128m worth of stock

Eris Lifesciences Limited (NSEI:ERIS) acquired dermatology portfolio of Glenmark Pharmaceuticals Limited from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for Rs 3.4 billion.

Third quarter 2023 earnings released: EPS: ₹7.49 (vs ₹7.41 in 3Q 2022)

Eris Lifesciences Limited to Report Q3, 2023 Results on Jan 17, 2023

Chairman & MD recently bought ₹109m worth of stock

High number of new directors

Second quarter 2023 earnings released: EPS: ₹8.84 (vs ₹8.71 in 2Q 2022)

Consensus forecasts updated

Eris Lifesciences Limited to Report First Half, 2023 Results on Oct 20, 2022

Now 20% undervalued

Insider recently sold ₹2.4m worth of stock

First quarter 2023 earnings released: EPS: ₹6.96 (vs ₹7.86 in 1Q 2022)

Eris Lifesciences Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on or Before 04 September 2022

Eris Lifesciences Limited to Report Q1, 2023 Results on Aug 05, 2022

Less than half of directors are independent

Eris Lifesciences Limited Announces Resignation of Vijaya Sampath as Independent Director

Eris Lifesciences Limited, Annual General Meeting, Sep 01, 2022

Insider recently sold ₹2.1m worth of stock

Consensus forecasts updated

Eris Lifesciences Limited (BSE:540596) agreed to acquire Oaknet Healthcare Private Limited for INR 6.5 billion.

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Insider recently sold ₹1.7m worth of stock

Second quarter 2022 earnings released: EPS ₹8.71 (vs ₹7.93 in 2Q 2021)

Insider recently sold ₹678k worth of stock

Chairman & MD recently bought ₹19m worth of stock

Insider recently sold ₹8.0m worth of stock

Price target increased to ₹810

First quarter 2022 earnings released: EPS ₹7.86 (vs ₹6.56 in 1Q 2021)

Insider recently sold ₹186m worth of stock

Full year 2021 earnings released: EPS ₹26.16 (vs ₹21.61 in FY 2020)

Insider recently sold ₹10m worth of stock

Price target raised to ₹721

Third quarter 2021 earnings released: EPS ₹6.64 (vs ₹4.62 in 3Q 2020)

Revenue beats expectations

Eris Lifesciences Limited to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: ₹598

Eris Lifesciences Limited Appoints Krishnakumar Vaidyanathan as an Additional Director Executive

New 90-day high: ₹550

Revenue and earnings beat expectations

Second quarter 2021 earnings released: EPS ₹7.93

Eris Lifesciences Limited to Report Q2, 2021 Results on Nov 03, 2020

Insider recently sold ₹968m worth of stock

Price target raised to ₹624

First quarter earnings released

New 90-day high - ₹540

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team